345 related articles for article (PubMed ID: 27545574)
1. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.
Zhao F; Olkhov-Mitsel E; van der Kwast T; Sykes J; Zdravic D; Venkateswaran V; Zlotta AR; Loblaw A; Fleshner NE; Klotz L; Vesprini D; Bapat B
J Urol; 2017 Feb; 197(2):335-341. PubMed ID: 27545574
[TBL] [Abstract][Full Text] [Related]
2. Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.
Zhao F; Vesprini D; Liu RSC; Olkhov-Mitsel E; Klotz LH; Loblaw A; Liu SK; Bapat B
Urol Oncol; 2019 May; 37(5):297.e9-297.e17. PubMed ID: 30777394
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.
Liu RSC; Olkhov-Mitsel E; Jeyapala R; Zhao F; Commisso K; Klotz L; Loblaw A; Liu SK; Vesprini D; Fleshner NE; Bapat B
J Urol; 2018 Jun; 199(6):1475-1481. PubMed ID: 29246734
[TBL] [Abstract][Full Text] [Related]
4. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
5. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection.
Rogers CG; Gonzalgo ML; Yan G; Bastian PJ; Chan DY; Nelson WG; Pavlovich CP
J Urol; 2006 Nov; 176(5):2280-4. PubMed ID: 17070312
[TBL] [Abstract][Full Text] [Related]
6. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
Connell SP; O'Reilly E; Tuzova A; Webb M; Hurst R; Mills R; Zhao F; Bapat B; Cooper CS; Perry AS; Clark J; Brewer DS
Prostate; 2020 May; 80(7):547-558. PubMed ID: 32153047
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive Detection of High Grade Prostate Cancer by DNA Methylation Analysis of Urine Cells Captured by Microfiltration.
Larsen LK; Jakobsen JS; Abdul-Al A; Guldberg P
J Urol; 2018 Oct; 200(4):749-757. PubMed ID: 29702096
[TBL] [Abstract][Full Text] [Related]
8. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
9. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
10. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
11. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
12. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
13. A urine-based methylation signature for risk stratification within low-risk prostate cancer.
Jatkoe TA; Karnes RJ; Freedland SJ; Wang Y; Le A; Baden J
Br J Cancer; 2015 Mar; 112(5):802-8. PubMed ID: 25695483
[TBL] [Abstract][Full Text] [Related]
14. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
15. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
16. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
Newcomb LF; Zheng Y; Faino AV; Bianchi-Frias D; Cooperberg MR; Brown MD; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Liss M; Morgan TM; Thompson IM; Wagner AA; Carroll PR; Nelson PS; Lin DW
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):438-445. PubMed ID: 30664734
[TBL] [Abstract][Full Text] [Related]
17. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
18. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging.
Bakavicius A; Daniunaite K; Zukauskaite K; Barisiene M; Jarmalaite S; Jankevicius F
Clin Epigenetics; 2019 Aug; 11(1):115. PubMed ID: 31383039
[TBL] [Abstract][Full Text] [Related]
19. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll PR; Feng Z; Gleave ME; Lance RS; Sanda MG; Thompson IM; Wei JT; Nelson PS;
Clin Cancer Res; 2013 May; 19(9):2442-50. PubMed ID: 23515404
[TBL] [Abstract][Full Text] [Related]
20. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]